CCA
IRLA

Catalyst Capital Advisors’s IRulya Therapeutics Inc. Common Stock IRLA Stock Holding History

Catalyst Capital Advisors’s Portfolio IRLA Stock Details IRLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-2
Closed -$14K – 465
2019
Q2 		$14K Buy
+2
New +$11.9K ﹤0.01% 292

Other funds holding IRLA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
SUT
SC US (TTGP) Menlo Park, California $31.9B AUM 28.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Alphabet Inc
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Manulife (Manufacturers Life Insurance)
Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $128B AUM 35.83% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Catalyst Capital Advisors's IRLA Position: Q3 2019 in Review

Catalyst Capital Advisors sold out of IRulya Therapeutics Inc. Common Stock (IRLA) in Q3 2019, closing a stake of 2 shares — an estimated $14K sold.

Catalyst Capital Advisors first reported a position in IRLA in Q2 2019 and held it in 1 quarter. The position peaked at $14K in Q2 2019. 39 funds tracked by Wall St. Rank hold IRLA as of Q3 2019.

  • Catalyst Capital Advisors reported no remaining IRulya Therapeutics Inc. Common Stock position as of Q3 2019 after selling out during the quarter.
  • Catalyst Capital Advisors sold 2 IRulya Therapeutics Inc. Common Stock shares in Q3 2019, an estimated $14K.
  • Catalyst Capital Advisors first reported a position in IRulya Therapeutics Inc. Common Stock in Q2 2019 and held it in 1 quarter.
  • Catalyst Capital Advisors's IRulya Therapeutics Inc. Common Stock position peaked at $14K in Q2 2019.
  • 39 funds tracked by Wall St. Rank held IRulya Therapeutics Inc. Common Stock as of Q3 2019.

Based on Catalyst Capital Advisors's 13F filing for Q3 2019, filed 5 Nov 2019.